- Record: found
- Abstract: not found
- Article: not found
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation
Ramón Corbalán ,
José Carlos Nicolau ,
José López-Sendon ,
Armando Garcia-Castillo ,
Rodrigo Botero ,
Gustavo Sotomora ,
Manuel Horna ,
Christian T. Ruff ,
Rose A. Hamershock ,
Laura T. Grip ,
Elliott M. Antman ,
Eugene Braunwald ,
Robert P. Giugliano
September 2018
September 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
There is limited information about the use of antithrombotic therapies and outcomes
of Latin American (LatAm) subjects with atrial fibrillation. The global ENGAGE AF-TIMI
48 (Effective Anticoagulation With Factor Xa Next Generation Atrial Fibrillation-Thrombolysis
In Myocardial Infarction 48) trial compared the efficacy and safety of edoxaban versus
warfarin over a median follow-up of 2.8 years.